Traws Pharma, Inc. TRAW
Traws Pharma, Inc. (Nasdaq: TRAW) is an infectious disease drug developer. Its lead program, ratutrelvir (TRX01), is in Phase 2 for COVID-19. Its next catalyst on record is tivoxavir marboxil: resolve FDA clinical hold (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tivoxavir marboxil — resolve FDA clinical hold (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ratutrelvir | COVID-19 | small molecule | Phase 2 |
| narazaciclib | solid tumors | small molecule | Phase 2 |
| rigosertib | EB-associated SCC (investigator-initiated) | small molecule | Phase 2 |
| tivoxavir marboxil | influenza (treatment and prophylaxis) | small molecule | Phase 1 |
Recent results and decisions
- Apr 15, 2026positive Phase 2a topline recap: equivalent time to sustained resolution with no viral rebound in PAXLOVID-eligible patients and faster resolution in ineligible patients (HR 1.31, 95% CI 0.78-2.20, p=0.018); final analysis underway.
Ratutrelvir demonstrated equivalent time to sustained treatment resolution with no viral rebounds in PAXLOVID® eligible subjects.
Filing - Feb 19, 2026clinical hold FDA placed the US IND for tivoxavir marboxil on clinical hold over concerns with the mutagenicity data package; no impact on ex-US studies.
the FDA informed the Company that its US IND for tivoxavir marboxil was being placed on clinical hold due to concerns with the mutagenicity data package.
Filing - Dec 17, 2025positive Interim Phase 2 (37 patients: 25 ratutrelvir, 12 PAXLOVID) showed numerically comparable time to symptom resolution, fewer adverse events and no rebound vs 1 of 12 on PAXLOVID; descriptive, no formal statistics.
No COVID-19 symptom or virologic rebound events have been observed to date in ratutrelvir-treated patients.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.